Novo Nordisk raised its full-year sales and profit outlook, expecting a smaller decline than previously forecasted, driven by strong GLP-1 product sales including the Wegovy pill. However, analysts remain cautious as the better-than-expected quarter was partly due to temporary rebate adjustments, and obesity drug sales were mostly in line with expectations. The company also reported disappointing clinical results for its next-generation weight-loss drug CagriSema, raising concerns about its long-term pipeline. Intense competition from Eli Lilly's newer obesity drugs continues to pressure Novo Nordisk's market position, leaving investors uncertain about sustainable growth prospects.
Deutsche Bank downgraded Novo Nordisk shares from 'hold' to 'sell', cutting the target price by 9% due to concerns over midterm growth and pipeline setbacks. The downgrade follows a mixed Q2 update and highlights worries about limited Medicare prescr...
In Q2 2026, Eli Lilly reported a strong 48% revenue growth driven by blockbuster obesity drugs Mounjaro and Zepbound, especially with rapid international expansion. Novo Nordisk faced challenges including shrinking U.S. sales, price cuts, layoffs, an...
Eli Lilly has introduced Foundayo, an oral GLP-1 pill for weight loss and type 2 diabetes, in UK pharmacies following recent approval. This tablet offers a convenient alternative to injections and is licensed for adults with certain BMI criteria or w...
Novo Nordisk's stock appears to have formed a long-term bottom as its turnaround gains momentum, with losses in market share to Eli Lilly stabilizing. Trading at just over 15 times forward earnings, the stock is valued at about half of Eli Lilly's mu...
